The central marker is IGF-1, which reflects growth hormone activity
For brand manufacturers managing lifecycle transitions, the analytical priority is identifying which drugs in the portfolio are Cost Plus-vulnerable meaning they have generic or biosimilar competitors with APIs available at manufacturing cost that Cost Plus could list at prices far below current protected pricing and which drugs have genuine clinical differentiation that would withstand direct cost-plus price competition
Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J
Rapid body change can trigger body image disruption, fear of regain, social anxiety around eating, and loss of food as a coping mechanism - all of which can produce significant anxiety
Some days you look up at dinner and realize you've barely eaten, and almost none of it was protein